Characterizing the impact of teriflunomide on adaptive immune cell subsets, repertoire and function in patients with relapsing-remitting MS: TERI-DYNAMIC

Wiendl H, Gross CC, Lindner M, Eschborn M, Weisser L, Posevitz-Fejfar A, Schulte-Mecklenbeck A, Van Wijmeersch B, Hupperts R, Lunven C, Brette S, Turner TJ, Klotz L (2015)

In: ECTRIMS, Barcelona, Spanien.

Abstract in digital collection (conference)

Comparison and Correlation of Two Proposed PML Risk Stratification Biomarkers for Long-term Natalizumab Treatment, Anti-JCV Antibody Index and L-selection (CD62L): A Retrospective Study

Schwab N, Schneider-Hohendorf T, Breuer J, Posevitz-Fejfar A, Wiendl H, Posevitz-Fejfar A (2014)

In: Neurology, 83(2).

Research article (journal)

The bile acid receptor FXR controls CNS autoimmunity in an IL-10-dependent fashion

Hucke S, Herold M, Liebmann M, Posevitz-Fejfar A, Kuhlmann T, Wiendl H, Klotz L (2014)

In: Journal of Neuroimmunology, 275(1-2, SI).

Research article (journal)

Fingolimod treatment promotes regulatory B-cell phenotype and function in multiple sclerosis

Gruetzke B, Hucke S, Wildemann B, Dehmel T, Kieseier B, Posevitz-feijfar A, Wiendl H, Klotz L (2014)

In: Journal of Neuroimmunology, 275(1-2, SI).

Research article (journal)

L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.

Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfár A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kümpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H (2013)

In: Neurology, 2013.

Research article (journal)

Publications

Operated by

Top-Links

Impaired DNAM-1/CD155 interaction in MS disrupts NK-mediated immune regulation of T-cell activity and is reconstituted by therapeutic modulation of the IL-2 receptor Gross CC, Schulte-Mecklenbeck A, Ruenzi A, Kuhlmann T, Posevitz-Fejfar A, Schwab N, Schneider-Hohendorf T, Held K, Konjevic M, Dornmair K, Hohlfeld R, Elkins J, Ziemssen T, Meuth SG, Wiendl H (2015) In: ECTRIMS, Barcelona, Spanien. Abstract in digital collection (conference)
Characterizing the impact of teriflunomide on adaptive immune cell subsets, repertoire and function in patients with relapsing-remitting MS: TERI-DYNAMIC Wiendl H, Gross CC, Lindner M, Eschborn M, Weisser L, Posevitz-Fejfar A, Schulte-Mecklenbeck A, Van Wijmeersch B, Hupperts R, Lunven C, Brette S, Turner TJ, Klotz L (2015) In: ECTRIMS, Barcelona, Spanien. Abstract in digital collection (conference)
The Neuroinflammation Biobank in the Department of Neurology, University Hospital Muenster, Germany Posevitz-Fejfar A, Wiendl H (2014) In: Biopreservation and Biobanking, 12(1). Research article (journal)
Comparison and Correlation of Two Proposed PML Risk Stratification Biomarkers for Long-term Natalizumab Treatment, Anti-JCV Antibody Index and L-selection (CD62L): A Retrospective Study Schwab N, Schneider-Hohendorf T, Breuer J, Posevitz-Fejfar A, Wiendl H, Posevitz-Fejfar A (2014) In: Neurology, 83(2). Research article (journal)
JCV index and L-selectin for natalizumab-associated PML risk stratification Schwab N, Schneider-Hohendorf T, Breuer J, Posevitz-Fejfar A, Wiendl H (2014) In: Multiple Sclerosis, 20(1). Research article (journal)
The bile acid receptor FXR controls CNS autoimmunity in an IL-10-dependent fashion Hucke S, Herold M, Liebmann M, Posevitz-Fejfar A, Kuhlmann T, Wiendl H, Klotz L (2014) In: Journal of Neuroimmunology, 275(1-2, SI). Research article (journal)
The pathophysiological role of cytotoxic CD8 T cells in Susac syndrome Bhatia U, Schneider-Hohendorf T, Posevitz-Fejfar A, Schwab N, Meuth SG, Wiendl H, Kleffner I, Gross CC (2014) In: 12th International Congress of Neuroimmunology (ISNI), Mainz, Deutschland. Abstract in digital collection (conference)
Fingolimod treatment promotes regulatory B-cell phenotype and function in multiple sclerosis Gruetzke B, Hucke S, Wildemann B, Dehmel T, Kieseier B, Posevitz-feijfar A, Wiendl H, Klotz L (2014) In: Journal of Neuroimmunology, 275(1-2, SI). Research article (journal)
JCV index and L-selectin for natalizumab-associated PML risk stratification Schwab N, Schneider-Hohendorf T, Breuer J, Posevitz-Fejfar A, Wiendl H (2014) In: Journal of Neuroimmunology, 275(1-2, SI). Research article (journal)
L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfár A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kümpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H (2013) In: Neurology, 2013. Research article (journal)